orchard
therapeutics
announces
new
clinical
data
sanfilippo
syndrome
type
accepted
oral
presentation
american
society
hematology
annual
meeting
boston
london
globe
newswire
orchard
therapeutics
nasdaq
ortx
global
gene
therapy
leader
today
announced
presentation
new
clinical
data
upcoming
american
society
hematology
ash
annual
meeting
held
virtually
december
oral
presentation
highlight
data
first
patient
treated
ongoing
study
investigational
ex
vivo
autologous
hematopoietic
stem
cell
hsc
gene
therapy
studied
treatment
mucopolysaccharidosis
type
iiia
progressive
metabolic
disease
approved
treatment
options
said
professor
robert
wynn
chief
investigator
royal
manchester
children
hospital
part
manchester
university
nhs
foundation
trust
pleased
see
encouraging
initial
results
including
evidence
engraftment
cells
important
first
step
investigation
whether
could
address
critical
unmet
needs
patients
look
forward
continuing
advance
program
add
growing
body
evidence
supporting
use
hsc
gene
therapy
treat
severe
neurometabolic
preliminary
results
first
patient
treated
show
evidence
engraftment
cells
sulphohydrolase
sgsh
enzyme
expression
multiple
lineages
reduction
heparan
sulfate
plasma
cerebrospinal
fluid
urine
initial
period
additional
data
update
trial
status
shared
time
oral
presentation
oral
presentation
details
autologous
stem
cell
gene
therapy
clinical
trial
mucopolysaccharidosis
type
iiia
trial
progress
publication
number
session
gene
editing
therapy
transfer
date
time
monday
december
pt
abstracts
available
online
ash
annual
meeting
website
mucopolysaccharidosis
type
iiia
also
known
sanfilippo
syndrome
type
rare
metabolic
disease
people
born
mutation
sulphohydrolase
sgsh
gene
healthy
helps
body
break
sugar
molecules
called
mucopolysaccharides
including
heparan
sulfate
buildup
mucopolysaccharides
brain
tissues
leads
intellectual
disability
loss
motor
function
occurs
approximately
one
every
live
births
life
expectancy
children
born
estimated
currently
approved
treatment
options
investigational
ex
vivo
autologous
hematopoietic
stem
cell
gene
therapy
studied
treatment
uses
modified
virus
insert
functional
copy
sgsh
gene
patient
cells
orchard
orchard
therapeutics
global
gene
therapy
leader
dedicated
transforming
lives
people
affected
rare
diseases
development
innovative
potentially
curative
gene
therapies
ex
vivo
autologous
gene
therapy
approach
harnesses
power
genetically
modified
blood
stem
cells
seeks
correct
underlying
cause
disease
single
administration
orchard
acquired
gsk
rare
disease
gene
therapy
portfolio
originated
pioneering
collaboration
gsk
san
raffaele
telethon
institute
gene
therapy
milan
italy
orchard
one
deepest
advanced
gene
therapy
product
candidate
pipelines
industry
spanning
multiple
therapeutic
areas
disease
burden
children
families
caregivers
immense
current
treatment
options
limited
exist
orchard
global
headquarters
london
headquarters
boston
information
please
visit
follow
us
twitter
linkedin
manchester
university
nhs
foundation
trust
manchester
university
nhs
foundation
trust
one
largest
nhs
trusts
england
leading
provider
specialist
healthcare
services
nine
hospitals
home
hundreds
world
class
clinicians
academic
staff
committed
finding
patients
best
care
treatments
information
available
availability
information
orchard
investors
others
note
orchard
communicates
investors
public
using
company
website
investor
relations
website
social
media
twitter
linkedin
including
limited
investor
presentations
investor
fact
sheets
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
orchard
posts
channels
websites
could
deemed
material
information
result
orchard
encourages
investors
media
others
interested
orchard
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
orchard
investor
relations
website
may
include
additional
social
media
channels
contents
orchard
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
statements
press
release
contains
certain
statements
orchard
strategy
future
plans
prospects
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
statements
include
express
implied
statements
relating
among
things
orchard
business
strategy
goals
therapeutic
potential
orchard
product
candidates
including
product
candidate
candidates
referred
release
statements
neither
promises
guarantees
subject
variety
risks
uncertainties
many
beyond
orchard
control
could
cause
actual
results
differ
materially
contemplated
statements
particular
risks
uncertainties
include
without
limitation
severity
impact
pandemic
orchard
business
including
clinical
development
commercial
programs
risk
one
orchard
product
candidates
including
product
candidate
candidates
referred
release
approved
successfully
developed
commercialized
risk
cessation
delay
orchard
ongoing
planned
clinical
trials
risk
orchard
may
successfully
recruit
enroll
sufficient
number
patients
clinical
trials
risk
prior
results
signals
safety
activity
durability
effect
observed
preclinical
studies
clinical
trials
replicated
continue
ongoing
future
studies
trials
involving
orchard
product
candidates
delay
orchard
regulatory
submissions
failure
obtain
marketing
approval
applicable
regulatory
authorities
orchard
product
candidates
receipt
restricted
marketing
approvals
risk
delays
orchard
ability
commercialize
product
candidates
approved
given
uncertainties
reader
advised
place
undue
reliance
statements
risks
uncertainties
faced
orchard
include
identified
heading
risk
factors
orchard
quarterly
report
form
quarter
ended
september
filed
securities
exchange
commission
sec
well
subsequent
filings
reports
filed
sec
statements
contained
press
release
reflect
orchard
views
date
hereof
orchard
assume
specifically
disclaims
obligation
publicly
update
revise
statements
whether
result
new
information
future
events
otherwise
except
may
required
law
contacts
investors
renee
leck
director
investor
relations
media
molly
cameron
manager
corporate
communications
media
hendriksz
jones
mortality
patients
sanfilippo
syndrome
orphanet
j
rare
dis
